UPDATE: Debunking the Myths: the Facts about Cotinine
This popular post from 2012 has been updated with recent research.
Genetics and Life Insurance - A View into the Microscope of Regulation
The use of genetic information for life, disability, critical illness and long-term care insurance is likely to increase in relevance. This report represents an attempt to understand key aspects of genetics, as well as limitations and controversies of its utilization in life insurance.
SCOR Housecalls: A Closer Look at Screening Tests
Inevitably we see cases in underwriting where the applicant has had an abnormality in a screening test and the follow-up testing is in progress or has been inconclusive. Those individuals are often postponed, while other applicants with similar characteristics who are not undergoing screening tests sail through the underwriting process without a second thought.
Are Functional Neurological Symptoms the “Great Deceivers”?
For insurers, neurological symptoms that remain unexplained by conventional medical investigations are a source of anxiety. While there is extensive guidance on managing risk in specific diagnoses, there is little when the patients’ experiences do not have a formal label.
Screening and Non-Small-Cell Lung Cancer
This article reviews key advances in the management of non-small-cell lung cancer and the clinical gains in outcomes as well as the ability to deliver personalized cancer treatment.
Electronic Health Records: Is Blockchain a Good Fit?
Even though paper records for most medical practices have evolved to digital, all of that data currently resides in silos, where consumers attempt to reconcile data among their providers and health payors. This can be challenging, as there is no single source that identifies where all of an individual’s health data resides, let alone the order in which it was entered.
Cancer Risks: Are We Getting Them Right?
Researching cancer mortality over the past few months has proved to be a bit of an eye-opener, and in three ways: firstly the level of excess mortality seen in a number of cancers, secondly the duration over which an extra risk persists, and thirdly that excess mortality may extend over a considerable period.